Investor Highlights

Current:

  • Investor Presentation - view here
  • Quarterly Shareholder Update - view here

Syntara Receives $5m R&D Tax Incentive

Clinical stage drug developer Syntara Limited (formerly Pharmaxis Ltd; ASX: PXS)1 has received a R&D tax incentive of $5,205,123 in relation to the 2023 financial year. The Company’s cash balances will increase by approximately $700k after repayment of the $4.4 million loan and associated charges advanced by Paddington Street Finance in August 2023.

Pharmaxis CEO Gary Phillips said, “The R&D tax incentive is a significant source of non-dilutive funding for the Company’s clinical development pipeline including PXS-5505 in myelofibrosis where the next arm of a phase 2 trial in combination with standard of care is expected to shortly dose its first patients.” 

  1. Syntara Limited was renamed from Pharmaxis Ltd on 4 December 2023. The new company name and code (SNT) will be effective on the ASX on 8 December 2023.
Read full media release - pdf

Syntara Limited name registered by ASIC

Clinical stage drug developer Syntara Limited today announced that the Australian Securities and Investment Commission has issued a Certificate of Registration on Change of Name from Pharmaxis Ltd to Syntara Limited.  This follows approval at last week’s 2023 annual general meeting where the resolution to change the name was supported by 98% of voting shareholders.

The change in the Company’s ASX code from PXS to SNT is currently being processed by the ASX, with trading under the new code expected to commence by Friday 8 December 2023.

Read full ASX announcement – pdf

Syntara doses first patient in Phase 2 trial of patients with sleep disorder at risk of Parkinson’s disease

Clinical stage drug developer Syntara1 today announced that the first patient has been dosed in its randomised double-blind placebo controlled Phase 2 study of the Syntara drug discovery PXS-4728 studying patients with isolated Rapid Eye Movement Sleep Behaviour Disorder (iRBD) who are at risk of Parkinson’s disease.

The first patient has been dosed in Sydney in a multi-national trial that is majority funded by the Parkinson’s Virtual Biotech, the international drug discovery and development program founded by Parkinson’s UK.

1. At the 2023 annual general meeting to be held on 28 November 2023, Pharmaxis shareholders will be asked to approve a change in the name of the company from Pharmaxis Ltd to Syntara Limited (ASX: SNT).
Read full media release - pdf

Pharmaxis Quarterly Shareholder Update and Investor Briefing

Pharmaxis Ltd (ASX: PXS) will release its Quarterly Shareholder Update on the morning of 31 October 2023.

Investors and analysts are invited to participate in a virtual investor briefing by the Company’s chief executive officer Mr Gary Phillips at 10.00am AEDT on Tuesday 31 October 2023.

The event will consist of a short presentation of the Company’s progress over the past quarter and future plans followed by a Q&A session from attendees.

The event is free to attend, and investors should register in advance using the following registration link: 

https://www.pharmaxis.com.au/investor-centre/investor-briefing/

Upon registration, instructions for joining the session will be sent via email.

To ensure as many questions as possible can be responded to in the allotted time, Pharmaxis welcomes investors to pre-submit questions by emailing them to: david.mcgarvey@pharmaxis.com.au

Read full media release - pdf

Notice of 2023 Annual General Meeting

The 2023 Annual General Meeting of Pharmaxis will be held as a virtual meeting on Tuesday, 28 November 2023 at 11:00 am (Sydney time).

The notice of meeting, explanatory statement and proxy form was made available to shareholders on 26 October 2023. The notice of meeting together with a sample proxy form is available here.

The 2023 statutory annual report is available here.